9.16
Precedente Chiudi:
$9.26
Aprire:
$9.37
Volume 24 ore:
492.37K
Relative Volume:
0.45
Capitalizzazione di mercato:
$969.91M
Reddito:
$247.00M
Utile/perdita netta:
$-249.00M
Rapporto P/E:
-2.9644
EPS:
-3.09
Flusso di cassa netto:
$-267.00M
1 W Prestazione:
+1.44%
1M Prestazione:
+6.26%
6M Prestazione:
-31.64%
1 anno Prestazione:
-36.70%
Arcus Biosciences Inc Stock (RCUS) Company Profile
Nome
Arcus Biosciences Inc
Settore
Industria
Telefono
(510) 694-6200
Indirizzo
3928 POINT EDEN WAY, HAYWARD, CA
Confronta RCUS con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
RCUS
Arcus Biosciences Inc
|
9.16 | 956.14M | 247.00M | -249.00M | -267.00M | -3.09 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-02-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2024-10-21 | Iniziato | H.C. Wainwright | Neutral |
2024-10-08 | Iniziato | Wells Fargo | Overweight |
2022-11-18 | Iniziato | BofA Securities | Neutral |
2022-10-11 | Iniziato | Morgan Stanley | Overweight |
2021-10-15 | Ripresa | BTIG Research | Buy |
2020-11-24 | Iniziato | Berenberg | Buy |
2020-11-23 | Iniziato | Evercore ISI | Outperform |
2020-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
2020-03-04 | Iniziato | Barclays | Overweight |
2019-11-12 | Iniziato | SunTrust | Buy |
2019-09-27 | Iniziato | Mizuho | Buy |
2019-05-24 | Ripresa | Citigroup | Buy |
2018-10-09 | Iniziato | Wedbush | Outperform |
2018-04-09 | Iniziato | Citigroup | Buy |
2018-04-09 | Iniziato | Goldman | Neutral |
2018-04-09 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Arizona State Retirement System Purchases 5,010 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
What drives Arcus Biosciences Inc. stock priceExceptional gains - jammulinksnews.com
Is Arcus Biosciences Inc. a good long term investmentPhenomenal trading returns - jammulinksnews.com
Arcus Biosciences Inc. Stock Analysis and ForecastTriple-digit returns - jammulinksnews.com
What analysts say about Arcus Biosciences Inc. stockExplosive earning power - jammulinksnews.com
Teacher Retirement System of Texas Has $143,000 Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Principal Financial Group Inc. Boosts Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Is Arcus Biosciences Inc. stock a good hedge against inflationFree Stock Investment Discussion Area - Newser
Trend Tracker for (RCUS) - news.stocktradersdaily.com
how arcus biosciences inc. stock performs during market volatilityTrending Stock Alert - Newser
How Arcus Biosciences Inc. stock performs during market volatilitySafe and Smart Investment Picks - Newser
What makes Arcus Biosciences Inc. stock price move sharplyFree Expert Investment Advice - Newser
Why Arcus Biosciences Inc. stock attracts strong analyst attentionElite Stock Shortlist - Newser
Allspring Global Investments Holdings LLC Has $144,000 Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Allspring Global Investments Holdings LLC Purchases 6,453 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Amalgamated Bank Boosts Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus wins FDA orphan status for cancer drug (RCUS:NYSE) - Seeking Alpha
Arcus Biosciences' Investigational Pancreatic Cancer Treatment Gets US FDA Orphan Drug Status - MarketScreener
Arcus Biosciences' Quemliclustat Gets Orphan Drug Status For Pancreatic Cancer - Nasdaq
Arcus' Pancreatic Cancer Drug Gets FDA Orphan Status as Phase 3 Trial Nears Full Enrollment - Stock Titan
Does Arcus Biosciences (NYSE:RCUS) Have A Healthy Balance Sheet? - simplywall.st
Arcus Biosciences' Quemliclustat Receives Orphan Drug Designatio - GuruFocus
Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment - MSN
State of Alaska Department of Revenue Boosts Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus
(RCUS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
GAMMA Investing LLC Buys 15,466 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences’ SWOT analysis: promising cancer therapy stock faces pivotal year - Investing.com
Arcus Biosciences Sees Unusually High Options Volume (NYSE:RCUS) - Defense World
Arcus Biosciences Holds Annual Stockholders Meeting - TipRanks
Arcus Biosciences Inc Inc. (RCUS) Price Performance: A Technical Analysis Perspective - investchronicle.com
Positive Signs As Multiple Insiders Buy Arcus Biosciences Stock - simplywall.st
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,872 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Cantor Fitzgerald Comments on RCUS FY2026 Earnings - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News - GuruFocus
Arcus Biosciences Inc Azioni (RCUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):